Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

Inclusion Criteria:

• Subjects with histologically or cytologically confirmed advanced hepatocellularcarcinoma (HCC), or The clinical diagnosis meets the American Association of LiverDiseases (AASLD) diagnostic criteria for hepatocellular carcinoma；

• Prior experience of targeted, immune, progression after conventional therapy, orintolerance (including TKIs,ICIs, chemotherapy, VEGF monoclonal antibody, or ICIs incombination with TKIs/VEGFs monoclonal antibody/chemotherapy)；

• Child-Pugh liver function rating within 7 days prior to the first dose of studydrug: Grade A or better grade B (≤ 7 points) ;

• Phase B or C as assessed by BCLC; or Phase III as assessed by CNLC;

• Within 4 weeks prior to the first dose, at least one measurable target lesionremained according to mRECIST v1.1；

• EGFR postive and RAS wildtype；

Exclusion Criteria:

• Dignosised as hepatic cholangiocarcinoma, mixed cell carcinoma, or fibrolamellarcell carcinoma；

• History of hepatic encephalopathy within 6 months prior to the first dose of thisstudy；

• Portal hypertension with endoscopic red signs, or those who are considered by theinvestigator to be at high risk of bleeding or who have had esophageal or gastricvariceal bleeding within 6 months prior to the first dose；

• Symptomatic brain or meningeal metastases (unless patient is treated> 3 months, noevidence of progression on imaging within 4 weeks prior to treatment, andtumor-related clinical symptoms is stable)